Glenn P. Sblendorio's Insider Trades & SAST Disclosures
Glenn P. Sblendorio's most recent trade in Mineralys Therapeutics Inc was a trade of 32,900 Stock Option done . Disclosure was reported to the exchange on Feb. 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Glenn P. Sblendorio.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 32,900 | 32,900 | - | - | Stock Option | |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 42,467 | 42,467 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 11,847 | 95,443 (0%) | 0% | 0 | Common Stock | |
| Mineralys Therapeutics Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 22,000 | 22,000 | - | - | Stock Option | |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.80 per share. | 07 Mar 2024 | 15,000 | 83,596 (0%) | 0% | 2.8 | 42,000 | Common Stock |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 15,000 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 30,474 | 30,474 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 8,584 | 95,303 (0%) | 0% | 0 | Common Stock | |
| Intercept Pharmaceuticals Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 12,547 | 12,547 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 8,111 | 31,558 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 15,000 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.32 per share. | 18 May 2023 | 15,000 | 86,719 (0%) | 0% | 3.3 | 49,800 | Common Stock |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 45,423 | 45,423 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 12,671 | 71,719 (0%) | 0% | 0 | Common Stock | |
| Intercept Pharmaceuticals Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 12,790 | 12,790 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 7,737 | 23,447 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2022 | 15,000 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.79 per share. | 04 Mar 2022 | 15,000 | 59,048 (0%) | 0% | 4.8 | 71,850 | Common Stock |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 36,111 | 36,111 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 10,115 | 44,048 (0%) | 0% | 0 | Common Stock | |
| Intercept Pharmaceuticals Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 12,089 | 12,089 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 7,029 | 15,710 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 18,574 | 18,574 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 5,855 | 33,933 (0%) | 0% | 0 | Common Stock | |
| Intercept Pharmaceuticals Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 2,966 | 2,966 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Glenn P. Sblendorio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 1,595 | 8,681 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges